Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Free Cash Flow (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Free Cash Flow data on record, last reported at -$2.2 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 13.72% year-over-year to -$2.2 million; the TTM value through Sep 2025 reached -$8.4 million, down 20.92%, while the annual FY2024 figure was -$6.6 million, 8.15% up from the prior year.
  • Free Cash Flow reached -$2.2 million in Q3 2025 per COEP's latest filing, up from -$2.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$59847.0 in Q3 2021 and bottomed at -$4.2 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$1.5 million, with a median of -$1.7 million recorded in 2023.
  • The widest YoY moves for Free Cash Flow: up 79.66% in 2022, down 1626.42% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$4.2 million in 2021, then soared by 79.66% to -$847352.0 in 2022, then tumbled by 99.89% to -$1.7 million in 2023, then grew by 15.19% to -$1.4 million in 2024, then crashed by 49.82% to -$2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$2.2 million in Q3 2025, -$2.4 million in Q2 2025, and -$2.4 million in Q1 2025.